AINEWS
A new RAND report argues existing law already permits broader oversight of synthetic genetic material through a new, lighter compliance tier for synthetic DNA — covering what the federal rules controlling dangerous pathogens and toxins currently
RAND, a federally focused research-policy body, is recommending the U.S. extend the federal biosecurity regime that already restricts dangerous pathogens and toxins to cover synthetic genetic material that today falls outside its reach. The proposal, published today as Volume 2 of a two-volume RAND study, would create a new, lighter compliance track the authors call "Tier 3."
The Federal Select Agent Program is the U.S. system that tightly controls who can possess, transfer, and work with a defined list of high-risk biological agents and toxins. Its reach is narrow: a roster of named viruses, bacteria, and toxins, plus the genes that encode certain toxin proteins. The framework was not designed to track synthetic DNA orders, gene fragments, or the genetic instructions that code for hazardous pathogen traits but do not, on their own, meet the existing "select agent" definition.
RAND's report aims to close that gap. It argues that FSAP's underlying statutes are broad enough, without new legislation, to bring more genetic material under the program's authority. The proposed Tier 3 track is built around three categories: additional viral genomes, genes that encode hazardous pathogen traits or toxins, and fragments of those genes. Each is a target that current oversight misses, and each is the kind of material that modern de novo synthesis and gene-enhancement techniques can now produce to order.
The "lighter" half of the design is where the report spends most of its effort. Tier 3 is framed as materially less burdensome than the full select-agent regime that governs today's high-containment labs. Compliance overhead and the possession, use, and transfer controls built around live select agents would over-penalize work with genetic sequences alone, the report argues; in practice, that would push legitimate research out of regulated channels rather than into them. RAND's stated goal is to capture the security benefit without imposing a compliance load the research community and gene-synthesis industry could not realistically absorb.
The risk RAND is trying to address has two parts. De novo chemical and enzymatic synthesis can now reconstruct dangerous viruses from written sequence data. Transfer of single hazardous genes can enhance otherwise ordinary microorganisms in ways that change what they can do. The report frames both capabilities as a public-health risk that the current FSAP roster, focused on finished pathogens and a small set of toxin genes, was not built to see. Together they describe a path to a dangerous biological capability that does not pass through any currently regulated select agent on the way.
The report does not announce a rulemaking, and the analysis stops short of claiming one is imminent. No specific cost figures, agency timelines, or named officials are attached to the proposal in the public text. What it offers is a mechanism: an existing statute, a new tier, and a designed-in attempt to keep the burden proportional. Policymakers and the agencies that administer FSAP can pick it up, set it down, or reshape it.
The agencies that run FSAP have not signaled an intent to act on the framework. The proposal now sits in front of them, on terms the report says existing law already supports. The next concrete move belongs to those regulators.